|
1
|
Formica JV and Regelson W: Review of the
biology of quercetin and related bioflavonoids. Food Chem Toxicol.
33:1061–1080. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Surh YJ: Cancer chemoprevention with
dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
No authors listed. Diet, nutrition and the
prevention of chronic diseases. World Health Organ Tech Rep Ser.
916:i–viii. 1–149. 2003.PubMed/NCBI
|
|
4
|
Rodriguez J, Yáñez J, Vicente V, Alcaraz
M, Benavente-García O, Castillo J, Lorente J and Lozano JA: Effects
of several flavonoids on the growth of B16F10 and SK-MEL-1 melanoma
cell lines: Relationship between structure and activity. Melanoma
Res. 12:99–107. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vijayababu MR, Arunkumar A, Kanagaraj P,
Venkataraman P, Krishnamoorthy G and Arunakaran J: Quercetin
downregulates matrix metalloproteinases 2 and 9 proteins expression
in prostate cancer cells (PC-3). Mol Cell Biochem. 287:109–116.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee WJ, Wu LF, Chen WK, Wang CJ and Tseng
TH: Inhibitory effect of luteolin on hepatocyte growth
factor/scatter factor-induced HepG2 cell invasion involving both
MAPK/ERKs and PI3K-Akt pathways. Chem Biol Interact. 160:123–133.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kamaraj S, Anandakumar P, Jagan S,
Ramakrishnan G and Devaki T: Modulatory effect of hesperidin on
benzo(a)pyrene induced experimental lung carcinogenesis with
reference to COX-2, MMP-2 and MMP-9. Eur J Pharmacol. 649:320–327.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balakrishnan A and Menon VP: Effect of
hesperidin on matrix metalloproteinases and antioxidant status
during nicotine-induced toxicity. Toxicology. 238:90–98. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sivagami G, Vinothkumar R, Bernini R,
Preethy CP, Riyasdeen A, Akbarsha MA, Menon VP and Nalini N: Role
of hesperetin (a natural flavonoid) and its analogue on apoptosis
in HT-29 human colon adenocarcinoma cell line - a comparative
study. Food Chem Toxicol. 50:660–671. 2012. View Article : Google Scholar
|
|
10
|
Ghorbani A, Nazari M, Jeddi-Tehrani M and
Zand H: The citrus flavonoid hesperidin induces p53 and inhibits
NF-κB activation in order to trigger apoptosis in NALM-6 cells:
Involvement of PPARγ-dependent mechanism. Eur J Nutr. 51:39–46.
2012. View Article : Google Scholar
|
|
11
|
Smith K: Pancreatic cancer: FASCINating
insights into the metastatic nature of pancreatic cancer. Nat Rev
Gastroenterol Hepatol. 11:1392014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar
|
|
13
|
Bardeesy N and DePinho RA: Pancreatic
cancer biology and genetics. Nat Rev Cancer. 2:897–909. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cano CE, Motoo Y and Iovanna JL:
Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma.
Sci World J. 10:1947–1957. 2010. View Article : Google Scholar
|
|
15
|
Lee J, Han SI, Yun JH and Kim JH:
Quercetin 3-O-glucoside suppresses epidermal growth factor-induced
migration by inhibiting EGFR signaling in pancreatic cancer cells.
Tumour Biol. 36:9385–9393. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harari PM: Epidermal growth factor
receptor inhibition strategies in oncology. Endocr Relat Cancer.
11:689–708. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vokes EE and Chu E: Anti-EGFR therapies:
Clinical experience in colorectal, lung, and head and neck cancers.
Oncology (Williston Park). 20(Suppl 2): 15–25. 2006.
|
|
18
|
Wajed SA, Laird PW and DeMeester TR: DNA
methylation: An alternative pathway to cancer. Ann Surg. 234:10–20.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tabernero J: The role of VEGF and EGFR
inhibition: Implications for combining anti-VEGF and anti-EGFR
agents. Mol Cancer Res. 5:203–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang S, Pashtan I, Tsutsumi S, Xu W and
Neckers L: Cancer cells harboring MET gene amplification activate
alternative signaling pathways to escape MET inhibition but remain
sensitive to Hsp90 inhibitors. Cell Cycle. 8:2050–2056. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Piccolo SR, Withers MR, Francis OE, Bild
AH and Johnson WE: Multiplatform single-sample estimates of
transcriptional activation. Proc Natl Acad Sci USA.
110:17778–17783. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee J, Ku T, Yu H, Chong K, Ryu SW, Choi K
and Choi C: Blockade of VEGF-A suppresses tumor growth via
inhibition of autocrine signaling through FAK and AKT. Cancer Lett.
318:221–225. 2012. View Article : Google Scholar
|
|
23
|
Lee J, Lee J, Yu H, Choi K and Choi C:
Differential dependency of human cancer cells on vascular
endothelial growth factor-mediated autocrine growth and survival.
Cancer Lett. 309:145–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamanaka Y, Friess H, Buchler M, Beger HG,
Uchida E, Onda M, Kobrin MS and Korc M: Overexpression of acidic
and basic fibroblast growth factors in human pancreatic cancer
correlates with advanced tumor stage. Cancer Res. 53:5289–5296.
1993.PubMed/NCBI
|
|
25
|
Nomura S, Yoshitomi H, Takano S, Shida T,
Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A,
et al: FGF10/FGFR2 signal induces cell migration and invasion in
pancreatic cancer. Br J Cancer. 99:305–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lieu C, Heymach J, Overman M, Tran H and
Kopetz S: Beyond VEGF: Inhibition of the fibroblast growth factor
pathway and antiangiogenesis. Clin Cancer Res. 17:6130–6139. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wagner M, Lopez ME, Cahn M and Korc M:
Suppression of fibroblast growth factor receptor signaling inhibits
pancreatic cancer growth in vitro and in vivo. Gastroenterology.
114:798–807. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang H, Hylander BL, LeVea C, Repasky EA,
Straubinger RM, Adjei AA and Ma WW: Enhanced FGFR signalling
predisposes pancreatic cancer to the effect of a potent FGFR
inhibitor in preclinical models. Br J Cancer. 110:320–329. 2014.
View Article : Google Scholar :
|
|
29
|
Berlin JD, Catalano P, Thomas JP, Kugler
JW, Haller DG and Benson AB III: Phase III study of gemcitabine in
combination with fluorouracil versus gemcitabine alone in patients
with advanced pancreatic carcinoma: Eastern Cooperative Oncology
Group Trial E2297. J Clin Oncol. 20:3270–3275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Heinemann V, Quietzsch D, Gieseler F,
Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M,
Heinrich B, et al: Randomized phase III trial of gemcitabine plus
cisplatin compared with gemcitabine alone in advanced pancreatic
cancer. J Clin Oncol. 24:3946–3952. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Louvet C, Labianca R, Hammel P, Lledo G,
Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, et
al GERCOR; GISCAD: Gemcitabine in combination with oxaliplatin
compared with gemcitabine alone in locally advanced or metastatic
pancreatic cancer: Results of a GERCOR and GISCAD phase III trial.
J Clin Oncol. 23:3509–3516. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Herrmann R, Bodoky G, Ruhstaller T,
Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A,
Pestalozzi B, et al Swiss Group for Clinical Cancer Research;
Central European Cooperative Oncology Group: Gemcitabine plus
capecitabine compared with gemcitabine alone in advanced pancreatic
cancer: A randomized, multicenter, phase III trial of the Swiss
Group for Clinical Cancer Research and the Central European
Cooperative Oncology Group. J Clin Oncol. 25:2212–2217. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al
National Cancer Institute of Canada Clinical Trials Group:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cascinu S, Verdecchia L, Valeri N, Berardi
R and Scartozzi M: New target therapies in advanced pancreatic
cancer. Ann Oncol. 17(Suppl 5): v148–v152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kindler HL, Friberg G, Singh DA, Locker G,
Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM,
et al: Phase II trial of bevacizumab plus gemcitabine in patients
with advanced pancreatic cancer. J Clin Oncol. 23:8033–8040. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Koay EJ, Truty MJ, Cristini V, Thomas RM,
Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, et al:
Transport properties of pancreatic cancer describe gemcitabine
delivery and response. J Clin Invest. 124:1525–1536. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Long J, Zhang Y, Yu X, Yang J, LeBrun DG,
Chen C, Yao Q and Li M: Overcoming drug resistance in pancreatic
cancer. Expert Opin Ther Targets. 15:817–828. 2011. View Article : Google Scholar : PubMed/NCBI
|
